|
Volumn 358, Issue 14, 2008, Pages 1427-1429
|
Regulating off-label drug use - Rethinking the role of the FDA
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTIBIOTIC AGENT;
ANTICONVULSIVE AGENT;
BEVACIZUMAB;
GABAPENTIN;
METFORMIN;
MONTELUKAST;
NEUROLEPTIC AGENT;
OLANZAPINE;
PAROXETINE;
QUETIAPINE;
RECOMBINANT ERYTHROPOIETIN;
ROFECOXIB;
TACROLIMUS;
AUTOIMMUNE DISEASE;
CARDIOVASCULAR DISEASE;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CHRONIC PAIN;
CLINICAL PRACTICE;
DEMENTIA;
DEPRESSION;
DIABETIC NEUROPATHY;
DRUG EFFECT;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE COST;
HEALTH CARE POLICY;
HEALTH HAZARD;
HERPES ZOSTER;
HUMAN;
OFF LABEL DRUG USE;
OVARY POLYCYSTIC DISEASE;
PRACTICE GUIDELINE;
PRESCRIPTION;
PRIORITY JOURNAL;
RISK ASSESSMENT;
SHORT SURVEY;
TREATMENT FAILURE;
UNSPECIFIED SIDE EFFECT;
|
EID: 41649086195
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp0802107 Document Type: Article |
Times cited : (298)
|
References (4)
|